End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
160.8 MXN | -.--% | -.--% | -.--% |
05-21 | Hansa Biopharma to Present Data At 2024 American Transplant Congress Annual Meeting | CI |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Sales 2024 * | 239M 22.58M 385M 30.89M | Sales 2025 * | 343M 32.34M 551M 44.24M | Capitalization | 2.78B 262M 4.47B 359M |
---|---|---|---|---|---|
Net income 2024 * | -735M -69.37M -1.18B -94.9M | Net income 2025 * | -712M -67.2M -1.14B -91.93M | EV / Sales 2024 * | 13.6 x |
Net Debt 2024 * | 474M 44.74M 762M 61.2M | Net Debt 2025 * | 733M 69.22M 1.18B 94.69M | EV / Sales 2025 * | 10.2 x |
P/E ratio 2024 * |
-3.82
x | P/E ratio 2025 * |
-4.53
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 11-30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.36% | 56.69B | |
-3.86% | 41B | |
+38.14% | 38.11B | |
-12.01% | 26.89B | |
+14.13% | 25.59B | |
-21.62% | 18.59B | |
+0.21% | 12.39B | |
+25.96% | 11.99B | |
+23.02% | 11.88B |
- Stock Market
- Equities
- HNSA Stock
- HNSA N Stock